OAR Box 1824

Prepped by Charmelle Mathews

Document Number:

(151) IV-D-200

Docket Number:

A-90-16

A-90-16 II-D-200

NATIONAL FOUNDATION FOR CANCER RESEARCH

7315 Wisconsin Avenue • Suite 332W • Bethesda, Maryland 20814 • 301/654-1250



Franklin C. Salisbury, J.D.
LL.D. (Hon.)
President & Chief
Executive Officer

Charles C. Pixley, M.D.
Vice President for
Scientific Administration

October 9, 1990

Mr. William K. Reilly
Administrator
Environmental Protection Agency
401 M Street, SW
Washington, DC 20460

Dear Mr. Reilly:

I would like to express support of the Ethyl Corporation for approval of their product HeTEC 3000 for use in gasoline in automobile engines. We have not made a study of the benefits which will come from the use of this additive to clean up the air and thus avoid various forms of cancer, but I am sure the company has and has included this information in the application.

I am sure that I join our 250,000 donors in urging you to promptly consider this application so that we may all benefit. I have not pre-judged the matter since we have no independent data, but we have become more than aware of the need for this type of gasoline additive to clean up the environment. Your work is very important and time is of the essence, so please encourage your people to be prompt in considering the approval.

Sincerely yours

Franklin C. Salisbury
President

FCS:eh

Enclosure

How We Work . . .

Among the prestigious institutions where NFCR has supported research are those on the following list. By their contributions of facilities, computer time, and co-operation they have helped make possible our "laboratory without walls" concept and earned a place on NFCR's honor role.

Australia
University of Sydney, Sydney

Austria
Universitat fur Graz, Graz

Belgium
Instituts Internationaux de Physique et de Chimie Solvay, Brussels

Canada
National Research Council, Ottawa
University of Alberta, Edmonton
University of Montreal, Montreal
University of Waterloo, Waterloo

England
Brunel University, Uxbridge
Medical Research Council, London
Oxford University, Oxford
University College School of Medicine, London
University of Leicester, Leicester

France
Institut de Biologie Physico-Chimique, Paris

Hungary
Debrecen University, Debrecen

Ireland
Our Lady of Lourdes, Int'l. Missionary Tr. Hospital, Drogheda
Royal College of Surgeons, Dublin
St. Laurence's Hospital, Dublin

Israel
Israel Institute for Biological Research, Ness-Ziona
The Weizmann Institute of Science, Rehovot

Italy
Universita di Genova, Genova
Universita di Siena, Siena
Universita di Torino, Torino

Japan
Jichi Medical School, Tochigi-Ken
Osaka University, Osaka
Technology University of Nagaoka, Nagaoka

Poland
Jagiellonian University, Krakow

Scotland
University of St. Andrews, St. Andrews
Vale of Leven Hospital, Alexandria

Sweden
University of Stockholm, Stockholm
Uppsala University, Uppsala

Switzerland
Institute for Integrative Biomedical Research, Zurich
Molecular Design International, Geneva

United States

California
California Institute of Technology, Pasadena
The Salk Institute for Biological Studies, San Diego
Stanford University, Stanford
University of California, Berkeley
University of California, San Francisco

Colorado
University of Colorado, Boulder
University of Colorado Health Sciences Center, Denver

Conneticut
Yale University, New Haven

District of Columbia
American University, Washington
Georgetown University, Washington
National Bureau of Standards, Washington

Florida
Florida State University, Tallahassee
University of Florida, Gainesville
University of Miami, Coral Gables

Illinois
Northwestern University, Evanston
University of Illinois, Urbana

Kentucky
University of Kentucky, Lexington

Louisiana
Louisiana State University, Baton Rouge
University of New Orleans, New Orleans

Maryland
Johns Hopkins University, Baltimore
National Institutes of Health, Bethesda

Massachusetts
Beth Israel Hospital, Harvard Medical School, Boston
Dana-Farber Cancer Institute, Harvard Medical School, Boston
Marine Biological Laboratory, Woods Hole
Sidney-Farber Cancer Institute, Harvard Medical School, Boston
Tufts University School of Medicine, Boston

New Hampshire
Dartmouth College, Hanover

New York
International Foundation for Cancer Research
City College of City University, New York City
Cold Spring Harbor Laboratory, Cold Spring Harbor
Cornell University, Ithaca
Columbia University, New York City
Down State Medical Center, New York City
General Electric Company, Schenectady
IBM Corporation, Kingston
Hofstra University, Hempstead
New York University, New York City
The Rockefeller University, New York City
Roswell Park Memorial Institute, Buffalo
State University of New York, Albany
W. Alton Jones Cell Science Center, Lake Placid

Oklahoma
Oklahoma State University, Stillwater

Pennsylvania
Carnegie-Mellon University, Pittsburgh
Hahnemann University, Philadelphia
Medical College of Pennsylvania, Philadelphia
Temple University, Philadelphia
University of Pittsburgh, Pittsburgh

Tennessee
University of Tennessee, Memphis

Texas
Texas A&M University, College Station
The University of Texas Health Science Center, San Antonio
The University of Texas M.D. Anderson Hospital and Cancer Institute, Houston

Virginia
Virginia Commonwealth University, Richmond
College of William and Mary, Williamsburg

Washington
Fred Hutchinson Cancer Center, Seattle

West Virginia
West Virginia University, Morgantown

Wisconsin
Institute of Paper Chemistry, Appleton
Medical College of Wisconsin, Milwaukee
University of Wisconsin-Madison, Madison

Wales
University College of North Wales, Bangor

West Germany
Free University of Berlin, Berlin
Hahn-Meitner Institut fur Kernforschung, Berlin
Institut fur Physiologische Chemie I, Dusseldorf
Max-Planck Institut fur Biophysikalische, Gottingen
Universitat Dusseldorf, Dusseldorf
Universitat Erlangen-Nurnberg, Erlangen
Universitat Essen, Essen

NATIONAL FOUNDATION
FOR CANCER RESEARCH
7315 Wisconsin Avenue
Suite 332W
Bethesda, Maryland 20814

Prepared by NFCR Staff:
Charles Pixley, MD
Elizabeth Hahn
Anna Belle Fulmer

NATIONAL FOUNDATION FOR CANCER RESEARCH



Who We Are . . .
What We Do . . .
How We Work . . .

Who We Are . . .

The National Foundation for Cancer Research (NFCR) was founded in 1974 by Franklin and Tamara Salisbury.

From the beginning the projects selected for funding have been those on the "cutting edge" — those innovative ideas and approaches which were not middle-of-the-road and thus were so often unable to obtain funding by the more conservative sources.

Being innovative themselves, they conceived the idea of a "laboratory without walls," which allowed scientists of several disciplines the flexibility to work on the problem in their own laboratories and yet share information and build on each other's work. This meant that the money went to the research itself and not into bricks and mortar.

Today NFCR scientists are a multinational, interdisciplinary group, who are individually distinguished in their own fields, but united through NFCR, in their commitment to understand the basic nature of cancer. When this is known it should be possible to prevent or interrupt the disease process.

The Foundation is a non-profit organization funded entirely by private donations from people all over the country who know that cancer is the most devastating disease of our time and that the only way we can find a cure is through research.

NFCR

Dr. Ivar Giaever, Nobel Laureate, is one of the NFCR Project Directors.

Dr. Charles C. Pixley, NFCR Vice President for Scientific Administration, shows world map of Foundation projects.

HRH Prince Charles presents NFCR President Franklin C. Salisbury with an Honorary LLD from the University of St. Andrews in recognition of his efforts to further cancer research.

What We Do . . .

NFCR concentrates its research on the truly basic questions: WHY does a normal cell turn cancerous? HOW does a normal cell differ from a cancer cell? WHAT can be done to change this process?

By focusing efforts on cellular research at the molecular and submolecular levels NFCR is taking an approach which many eminent scientists feel has the greatest potential for the arrest and prevention of cancer.

The Foundation fosters new ideas by encouraging collaboration between scientists in different fields: theoretical studies, biophysics, chemistry, biochemistry, cell biology, biochemical pathology, pharmacology, oncology, genetic engineering and immunology.

Research projects are periodically reviewed and selected by a committee of distinguished university scientists (not eligible for NFCR support). Hundreds of investigators have received NFCR funding, including four Nobel Laureates.

The NFCR also sponsors scientific symposia, workshops and conferences which not only foster the exchange of new ideas and information within the greater scientific research community, but also provide up-to-date public information on cancer research progress.